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Abstract
Angiogenesis is essential for solid tumour growth, whilst the molecular profiles of tumour blood vessels have been reported
to be different between cancer types. Although presently available anti-angiogenic strategies are providing some promise
for the treatment of some cancers it is perhaps not surprisingly that, none of the anti-angiogenic agents available work on
all tumours. Thus, the discovery of novel anti-angiogenic targets, relevant to individual cancer types, is required. Using
Affymetrix microarray analysis of laser-captured, CD31-positive blood vessels we have identified 63 genes that are
upregulated significantly (5–72 fold) in angiogenic blood vessels associated with human invasive ductal carcinoma (IDC) of
the breast as compared with blood vessels in normal human breast. We tested the angiogenic capacity of a subset of these
genes. Genes were selected based on either their known cellular functions, their enriched expression in endothelial cells
and/or their sensitivity to anti-VEGF treatment; all features implicating their involvement in angiogenesis. For example,
RRM2, a ribonucleotide reductase involved in DNA synthesis, was upregulated 32-fold in IDC-associated blood vessels; ATF1,
a nuclear activating transcription factor involved in cellular growth and survival was upregulated 23-fold in IDC-associated
blood vessels and HEX-B, a hexosaminidase involved in the breakdown of GM2 gangliosides, was upregulated 8-fold in IDC-
associated blood vessels. Furthermore, in silico analysis confirmed that AFT1 and HEX-B also were enriched in endothelial
cells when compared with non-endothelial cells. None of these genes have been reported previously to be involved in
neovascularisation. However, our data establish that siRNA depletion of Rrm2, Atf1 or Hex-B had significant anti-angiogenic
effects in VEGF-stimulated ex vivo mouse aortic ring assays. Overall, our results provide proof-of-principle that our approach
can identify a cohort of potentially novel anti-angiogenic targets that are likley to be, but not exclusivley, relevant to breast
cancer.
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Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing vasculature, is critical for tumour growth and cancer
progression, implying that anti-angiogenic drugs are likely to be of
importance in the treatment of neoplasia [1,2]. Angiogenesis is
influenced by several growth factors, such as vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF)
[3,4]. Indeed, anti-angiogenic strategies targeting VEGF have
shown some considerable promise, but improvements are still
needed. Identifying gene expression changes between tumour-
associated blood vessels and those in normal tissues may provide us
with new anti-angiogenic targets. Some data have suggested that
blood vessels supplying tumours express genes not expressed in
blood vessels in normal tissues [5–9]. Although results from such
studies have yet to be verified, given that the molecular ‘zipcodes’
of tumour-associated vasculatures may be different between cancer
types, identifying anti-angiogenic targets relevant to tumour types
may have significant benefits over currently available strategies
[10–14].
Tumours consist of a mixture of cancer and stromal compart-
ments, which have their own gene expression profiles and, as such,
analysis of whole tumours is not necessarily appropriate when
designing anti-angiogenic agents [15–24]. In addition cell culture
based studies are open to the criticism that they induce molecular
changes, making results less relevant to the disease in the whole
organism [7,8]. An alternative method is to use laser capture
microdissection (LCM), which allows for the isolation of specific
tissues or cells directly from whole tissue sections [5,9,25–28].
LCM has been used successfully for PCR- and microarray analysis
of specific cell populations including blood vessels [5,9,25,27,29].
CD31 (PECAM1) is known to be a suitable marker for the
identification of angiogenic blood vessels in many tissues, including
breast cancer and is used as such in the pathological analysis of
breast cancer [30,31].
Here we have developed a method for the detection of CD31 in
human breast cancer and normal human breast, followed by LCM
of CD31-positive blood vessels and subsequent expression array
analysis. We have identified 7 downregulated and 63 upregulated
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genes associated with human breast cancer CD31-postive blood
vessels. Our data has demonstrated that at least 3 of these genes,
Rrm2, Atf1 and Hex-B, when depleted in mouse aortic rings, have
anti-angiogenic effects, validating our approach to the discovery of
new anti-angiogenic targets.
Methods
Ethics Statement
Frozen human breast tissues were obtained from Barts and The
London School of Medicine and Dentistry, Queen Mary
University and Oxford John Radcliffe Hospital Biobank, a Human
Tissue Authority Licensed Research Tissue Bank (HTA License
number 12217). All patients gave informed written consent. For
samples from Queen Mary University, the project was covered by
ethics reference 05/Q0403/199 from the North East London
ethics committee. For samples from Oxford John Radcliffe
Hospital Biobank, the project was covered by ethics reference
09/H0606/5 from the National Research ethics service Oxford-
shire. All animals were used in accordance with UK Home Office
regulations and approved by the Queen Mary University of
London and Oxford University ethics committee.
Breast tissue, preparation and processing
Twenty-eight breast IDC and 13 normal breast samples were
screened for suitability. Eight mm sections of tissue from frozen
breast blocks were first trimmed using a cryostat set at 230uC to
test RNA quality and morphology using haematoxylin staining.
Only samples with RNA integrity number (RIN) of 6 or more were
used (see RNA extraction protocol). RNase-free technique was
used throughout the procedure using RNase-ZAP (Ambion). Up to
3 sections 8 mm thick were cut with the cryostat and placed on a
treated PALM membrane polyethylene naphthalate slides (PALM
Microlaser Technologies, Bernried, Germany). Up to 20 slides
were collected per patient. Slides were stored on dry ice until
sectioning was finished then immediately transferred to a 280uC
freezer for long-term storage. The slides were stored up to
2 months before LCM.
Immunohistochemistry for LCM
Immunochemistry staining of sections for LCM was optimised
for maintenance of RNA quality. For endothelial-specific CD31
staining, sections were fixed in acetone (5 min, 220uC), and
incubated with primary antibody anti-CD31 (WM59, BD
PharmingenTM) 1:5 for 5 min followed by two PBS (Ambion)
washes, biotinylated secondary antibody (Vectastain Universal
Quick kit PK8800 – Vector labs) for 5 min, two PBS washes,
StreptABCcomplex/HRP (Vectastain Universal Quick kit
PK8800 – Vector labs) for 5 min, two PBS washes, amino-ethyl-
carbazole (AEC, Dako K3464) for 5 min, two water washes
(Ambion), Cresyl Violet 1:20 in water (Ambion, AM1935) for
30 sec, two water washes and finally air-dried for up to 1 min with
a hair-dryer. All antibody steps and AEC contained the RNase
inhibitor 0.4 U/mL RNase Protector (Roche; Indianapolis, IN),
and all PBS and water were nuclease free. All steps were carried
out in RNase-free conditions. LCM was carried out immediately
using the Zeiss Axiovert 135 with PALM Microbeam 3 System
and RoboSoftware (Carl Zeiss Europe). In combination with
CD31 expression, blood vessels were selected by morphology,
where only small vessels with lumens or branching structures were
collected. This method allowed for the isolation of whole blood
vessel sections that include both endothelial cells and supporting
cells. Approximately 200 blood vessels were captured onto
adhesive lids of eppendorfs (PALM) per slide and lysed in 50 ml
RNA lysis buffer (Qiagen RNeasy Micro Kit). Up to 3 hr of LCM
was spent per slide. Blood vessels from up to 20 slides per patient
were captured for combined RNA extraction. Details for staining
for CD68 and CD31 are in Methods S1.
RNA extraction, reverse transcriptase and real-time PCR
RNA extraction was carried out using Qiagen RNeasy Mini or
Micro Kit following the manufacturer’s instructions with DNase
treatment (Qiagen). RNA concentration and quality was analysed
with Agilent 2100 Bio-analyzer (Agilent Technologies, Palo Alto,
CA) using Agilent Pico kit or Nano kit and assessed using an
Agilent software algorithm that allows the calculation of RIN with
a numbering system from 1 to 10, with 1 being the most degraded
Figure 1. RNA profile and quality of frozen breast IDC samples. RNA profiles of (A) IDC and (B) normal breast samples using Agilent
bioanalyser. RNA bands correspond to 28S and 18S rRNA. RNA quality was rated according to the RNA integrity number (RIN).
doi:10.1371/journal.pone.0044294.g001
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Figure 2. Combined CD31-immunostaining and LCM of blood vessels in breast tissue. (A) Normal and IDC breast sections were stained
with anti-CD31 monoclonal antibody using our modified staining protocol. Blood vessels are stained in red with CD31-AEC (Arrowheads, blood
vessels), and cell nuclei are stained in blue with Cresyl Violet. (B) PALM laser microdissection of CD31-positive blood vessels. (C) Agilent bioanalyser of
RNA from LCM blood vessels compared with unstained control and CD31 stained sections. RNA quality was rated according to the RNA integrity
number (RIN). Histograms correspond to RNA bioanalyser profiles. (D) Real-time PCR of CD31 mRNA expression in LCM blood vessels from breast
tissue confirms high level of CD31 in laser captured material. CD31 mRNA expression was given as a ratio to G6PD mRNA (internal control), and the
data represented relative to unstained sample control (n = 2, 6 fold range, *p,0.05).
doi:10.1371/journal.pone.0044294.g002
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and 10 being the most intact [32]. Only samples that had high
RIN number of above 6 were considered for analysis. cDNA from
RNA was synthesised using the High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA) following the manufactur-
er’s instructions. To determine if LCM captured samples had
blood vessels, real-time PCR was used to quantify the expression of
CD31 mRNA. Real-time PCR reactions were performed using the
Applied Biosystem StepOnePlusTM (Applied Biosystems, Foster
City, CA) with SYBR green (Invitrogen). Primers against CD31 59-
AGAAAACCACTGCAGAGTACCAG-39 forward and 59-
GGCCTCTTTCTTGTCCAGTGT-39 reverse (Invitrogen, Pais-
ley, UK). Glucose-6-phosphate dehydrogenase (G6PD) was used as
a reference gene using primers 59-AACAGAGT-
GAGCCCTTCTTAA-39 forward and 59-GGAGGCTGCAT-
CATCGTACT-39 reverse. Additional primers for validating
differentially expressed genes are in supporting information
(Methods S1 and Table S1).
Microarray experiments
RNA from LCM samples was amplified using the WT (whole
transcriptome)-Ovation Pico RNA Amplification system (NuGEN)
with a 2-cycle amplification following the manufacturer’s instruc-
tions, and cDNA was fragmented and labelled using the FL-
Ovation cDNA Biotin Module V2 kit. Although 2-cycle amplifi-
cation may introduce a bias over 1-cycle, we were careful to
control for this by amplifying both the cancer and normal samples
identically. Labelled cDNA Microarray hybridisations were
performed on HG-U133 Plus 2 arrays (Affymetrix) and gene
expression data was analysed using Bioconductor 2.2 [33] running
on R2.7.1. [34]. Normalised probeset expression measures were
calculated using the ‘Affy’ package’s Robust Multichip Average
(RMA) default method. Differential gene expression was assessed
between replicate groups using an empirical Bayes t-test as
implemented in the ‘limma’ package [35]. The resultant p-values
were adjusted for multiple testing using the False Discovery Rate
(FDR) Benjamini and Hochberg method [36], where any probe
sets that exhibited an adjusted p-value FDR q,0.05 were called
differentially expressed. Two-dimensional hierarchical clustering
of expression data using differentially expressed genes was
performed using a Pearson correlation distance matrix and
average linkage clustering [34]. All data have been deposited in
a public database. Affymetrix data was also analysed with
Ingenuity Pathways Analysis software (IngenuityH Systems, www.
ingenuity.com). Additional Microarray analysis was carried on
human U87 xenograft samples (Methods S1).
Endothelial specific genes
All genes found to be differentially expressed from the
microarray results were compared to genes selectively expressed
in endothelial cells from cDNA and SAGE library analysis. Briefly,
libraries were divided into two pools; pool 1 contained endothelial
cell libraries and pool 2 libraries of non-endothelial normal
primary cell isolates. In-silico subtraction, employing maximum
likelihood statistics, between both pools found endothelial-
enriched genes and these results were used to prioritise LCM
candidate genes. See Herbert et al. 2008 for a full description of
methods [37]. The results shown are the FDR-adjusted q-values
[38].
Immunohistochemistry for GPR164 and LIFR
Frozen sections (8 mm thickness) were fixed in acetone for 5 min
(220uC), washed in PBS, blocked with 5% BSA/PBS for 30 min
and incubated with primary antibodies (LIFR: 1/50, Santa Cruz
sc-659; GPR164: 1/400, Abcam ab65759, CD31: 1/100, BD
Pharmingen 550389) overnight at 4uC. Sections were washed in
PBS before adding the appropriate fluorescent secondary
antibodies for 1 hr at room temperature and mounted with
ProLong GoldH anti-fade reagent with DAPI (Invitrogen P-
36931). Sections were imaged using a LSM 510 inverted confocal
laser-scanning microscope (Carl Zeiss Ltd., UK). For each
channel, the detector gain and amplifier offset were set to display
the full range of signal intensities within and between samples and
then adjusted to exclude background. These settings were kept the
same when imaging all the patients’ samples. Consecutive sections
from each patient were also stained with appropriate IgG control
antibodies and imaged using the same settings. Staining was
quantified in the CD31-positive blood vessels using ImageJ
software. Blood vessels were identified by their CD31 positivity
and the corresponding GPR164 or LIFR fluorescence intensity
per pixel was measured. ImageJ software was used to evaluate the
mean relative intensity of fluorescence for these markers in blood
vessels within the sections. In order to normalise blood vessel-
specific immunostaining for GPR164 and LIFR between samples,
it was necessary to correct for differences in non-specific staining.
This was done by analysing the mean fluorescence intensity of IgG
non-specific staining in the CD31-positive blood vessels and then
Figure 3. Affymetrix data from LCM blood vessels. (A) Hierarchal clustering of laser captured blood vessels from 4 normal and 5 IDC samples
with percentage present call rate. (B) Heat map that shows the trend in expression of 73 probe-sets, 70 genes across the six samples. The blue
indicates under-expression while the red indicates over-expression with gene name and accession number given.
doi:10.1371/journal.pone.0044294.g003
Table 1. Seven of the most downregulated genes in breast IDC associated blood vessels with q,0.05.
Gene Accession Description Fold change
TACC1 AL133564 Transforming, acidic coiled-coil containing protein 1 0.09
CUGBP2 R49146 CUG triplet repeat, RNA binding protein 2 0.08
TSHZ2 AU147926 Teashirt zinc finger homeobox 2 0.07
HIF3A AK021881 Hypoxia inducible factor 3, alpha subunit 0.05
LIFR NM_002310 Leukemia inhibitory factor receptor alpha 0.04
ANKRD29 AI307802 Ankyrin repeat domain 29 0.04
CD300LG NM_145273 CD300 molecule-like family member g 0.01
doi:10.1371/journal.pone.0044294.t001
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Table 2. Sixty-three of the most upregulated genes in breast IDC associated blood vessels with greater than 5 fold change and
q,0.05.
Gene Accession Description Fold change
AI343467 NA 72
BC042986 NA 65
C2orf37 AK021599 Chromosome 2 open reading frame 37 64
H2AFZ NM_002106 H2A histone family, member Z 40
TOP2A AU159942 Topoisomerase (DNA) II alpha 170kDa 39
EDG3 AA534817 Endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 37
PCNA NM_002592 Proliferating cell nuclear antigen 32
RRM2 BE966236 Ribonucleotide reductase M2 polypeptide 32
FN1 AJ276395 Fibronectin 1 31
CENPF U30872 centromere protein F, 350/400ka (mitosin) 25
TMTC3 AA428286 Transmembrane and tetratricopeptide repeat containing 3 25
MRPL15 NM_014175 Mitochondrial ribosomal protein L15 24
ATF1 CA337502 Activating transcription factor 1 23
NRAS NM_002524 Neuroblastoma RAS viral (v-ras) oncogene homolog 22
PCDH17 N69091 Protocadherin 17 22
C1orf107 NM_014388 Chromosome 1 open reading frame 107 21
PRO1933 AF132203 PRO1933 21
MLF1IP NM_024629 MLF1 interacting protein 20
TMED2 NM_006815 Transmembrane emp24 domain trafficking protein 2 20
ATP5O NM_001697 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 19
XIAP N30645 X-linked inhibitor of apoptosis 19
ABCD3 BC009712 ATP-binding cassette, sub-family D (ALD), member 3 17
TUBB BC001002 Tubulin, beta 17
SLMO2 BF032213 Slowmo homolog 2 (Drosophila) 17
YES1 NM_005433 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 17
SH3BGRL2 BE550855 SH3 domain binding glutamic acid-rich protein like 2 17
ATP6AP2 NM_005765 ATPase, H+ transporting, lysosomal accessory protein 2 16
MGC9913 BE855713 Hypothetical protein MGC9913 15
MPZL1 BF978611 Myelin protein zero-like 1 15
DKFZP686E2158 BE613001 Hypothetical protein LOC643155 15
EIF2S1 BC002513 Eukaryotic translation initiation factor 2, subunit 1 alpha 15
SERF1A AF073518 Small EDRK-rich factor 1A (telomeric) 14
CETN2 BC005334 Centrin, EF-hand protein, 2 13
DLG7 NM_014750 Discs, large homolog 7 (Drosophila) 13
SLC1A4 W72527 Solute carrier family 1 (glutamate/neutral amino acid transporter),
member 4
13
SMARCA2 NM_003070 SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 2
13
ATP6V1C1 NM_001695 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 13
GPR137B NM_003272 G protein-coupled receptor 137B 13
C1orf149 NM_022756 Chromosome 1 open reading frame 149 12
UBE2J1 NM_016021 Ubiquitin-conjugating enzyme E2, J1 12
CCDC117 AW070234 Coiled-coil domain containing 117 12
KLHL12 AK024412 Kelch-like 12 (Drosophila) 11
EXOC8 AI168350 Exocyst complex component 8 11
GPR164 AI694767 Olfactory receptor, family 51, subfamily E, member 1 11
COL4A2 X05610 Collagen, type IV, alpha 2 10
YIPF5 AW001618 Yip1 domain family, member 5 10
EIF3J BC002719 Eukaryotic translation initiation factor 3, subunit J 9
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subtracting from the specific staining obtained with GPR164 or
LIFR for each sample. This allowed us to overcome the
heterogeneity of the non-specific staining between different
patients. Four to five blood vessels from 6 normal breast and 6
breast IDC samples were quantified. Results are shown as the
mean relative intensities of the samples 6 s.e.m. Statistical
significance was determined by Student’s t-test at a level of
p,0.05.
Ex vivo Aortic Ring Assays
Thoracic aortas were isolated from adult C57BL6 mice and
prepared for culture as described previously [39]. Depletion of
target genes with siRNA was carried out essentially as described in
Reynolds et al., [40]. Microvessels growth on aortic rings were
quantified between 6–10 days. After maximum sprouting capacity
was achieved, aortic rings were fixed and stained with BS1-lectin
as described in Reynolds et al., [41].
Results
Laser Capture Microdissection of blood vessels from
human breast tissue
Twenty-eight human IDC samples and 13 normal human
breast samples were obtained and snap-frozen in liquid nitrogen.
Although using snap-frozen tissue probably provides the best
preservation of RNA without fixation, there are many factors, such
as handling time and especially the interval between surgery and
snap-freezing the sample, that can affect the quality of the RNA in
breast tissue. Out of all the samples collected, only 16 IDC samples
and 6 normal breast samples had high enough RNA quality (a
RIN above 6) for further analysis according to Agilent lab-on-a-
chip pKit bioanalyser (Figure 1A and B).
An anti-CD31 antibody was used to identify the blood vessels in
normal and breast IDC sections. This was in preference to other
markers, such as CD146, since CD146, in addition to its
Table 2. Cont.
Gene Accession Description Fold change
FYTTD1 BF576005 Forty-two-three domain containing 1 9
SNTB1 BG484314 Syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic
component 1)
9
LOC401233 BI868572 Similar to HIV TAT specific factor 1; cofactor required for Tat activation of
HIV-1 transcription
9
SMURF2 AU157259 SMAD specific E3 ubiquitin protein ligase 2 8
HEXB NM_000521 Hexosaminidase B (beta polypeptide) 8
NCK2 BC000103 NCK adaptor protein 2 8
BF676081 NA 7
SCYL2 NM_017988 SCY1-like 2 (S. cerevisiae) 7
OLFML2A AL050002 Olfactomedin-like 2A 7
LIN9 BF697734 Lin-9 homolog (C. elegans) 7
WASL AL523820 Wiskott-Aldrich syndrome-like 6
PLXNA2 AI694545 Plexin A2 6
FBXO21 AK001699 F-box protein 21 6
HMMR NM_012485 Hyaluronan-mediated motility receptor (RHAMM) 6
FAM33A BE048371 Family with sequence similarity 33, member A 5
FIGNL1 NM_022116 Fidgetin-like 1 5
doi:10.1371/journal.pone.0044294.t002
Table 3.Molecular and Cellular Function Ingenuity analysis of
differentially regulated genes in human breast IDC associated
blood vessels.
Name p-value Molecules
Cellular Assembly and Organisation 3.63E-07 11
Cellular Function and Maintenance 2.63E-05 9
Protein Synthesis 3.85E-05 8
Cell Cycle 2.12E-04 7
Energy Production 2.71E-04 3
doi:10.1371/journal.pone.0044294.t003
Table 4. Canonical Ingenuity pathway analysis of
differentially regulated genes in human breast IDC associated
blood vessels.
Pathway p-value Molecules
Role of BRCA1 in DNA Damage Response 0.008 2
Ephrin Receptor Signalling 0.011 3
Protein Ubiquitination Pathway 0.013 3
Integrin Signalling 0.015 3
Axonal Guidance Signalling 0.017 4
BMP Signalling Pathway 0.018 2
TGF-b Signalling 0.019 2
VEGF Signalling 0.021 2
doi:10.1371/journal.pone.0044294.t004
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expression in the vascular compartment, is expressed on a subset
of epithelial cells in malignant breast [42]. Lastly, comparison of
PECAM staining directly with CD146 staining has shown that,
CD146 identifies a substantially higher number of non–blood
vessels structures in serial sections of breast cancer [43]. Thus the
use of PECAM as a marker of endothelial cells, together with
blood vessel selection according to morphology, likely provides us
with a highly specific method to detect blood vessels in breast
cancer. The quality of the immunodetection was excellent for both
breast IDC and normal sections and blood vessels were identified
easily for LCM (Figure 2 A and B). By using a combination of
both CD31-positivity and morphology, to select blood vessels with
a lumen or a branched structure, we avoided the possibility of
selecting myeloid cells that are CD31/CD68 double positive.
(Methods S1 and Figure S1).
Although good quality RNA was obtained from LCM samples
(Figure 2C), up to 70% of total RNA was lost following
immunostaining compared with unstained equal sized tissue
samples. Thus, using this staining protocol, 7 out of 16 cancer
and 5 out of 6 normal samples gave sufficiently good RNA quality
and quantity for Affymetrix analysis (Methods S1 and Fig-
ure S2). Using real-time PCR we confirmed that the tissue
samples isolated by LCM were enriched significantly for CD31
when compared with whole control unstained sections (p,0.05,
Figure 2D).
Identifying genes that are differentially regulated in
blood vessels associated with human breast cancer
Using the WT (whole transcriptome) Ovation Pico RNA
Amplification system, we amplified RNA levels to 2.6–6.3 mg of
labelled cDNA from 5 IDC and 4 normal breast samples. The
yield from the remainder of the samples was too low for utilisation.
For Affymetrix gene expression analysis we compared laser-
captured CD31-positive blood vessels from 5 IDC samples (2.8–
6.3 mg cDNA) with vessels from 4 normal breast samples
(2.623.9 mg cDNA). Other studies using frozen tissues gave an
average present call rate of 26% [44]. We obtained present call
rates of up to 59.2% from our samples, suggesting a good level of
hybridisation in our experiments. Hierarchal clustering revealed
that 3 IDC and 3 normal breast associated blood vessel samples
correlated well and clustered into normal and cancer groups
(Figure 3A). Samples with low percent call rates corresponded to
outliers that were omitted from the subsequent analysis
(Figure 3A). In total, 73 probe sets representing 70 genes were
differentially expressed between normal and breast IDC associated
blood vessels (Figure 3B). Seven genes were downregulated (more
than 10 fold) and 63 genes upregulated (5–72 fold) with FDR
q,0.05 (Tables 1 and 2). Using Ingenuity Pathway Analysis, we
found that the 70 differentially expressed genes in human breast
IDC associated blood vessels have molecular, cellular and
signalling functions many of which are involved in angiogenesis
(Tables 3 and 4). Thus the upregulated gene list provided us with
a cohort of potentially anti-angiogenic targets.
Table 5. List of genes enriched in endothelial cells in LCM
samples.
Gene Accession
Endothelial EST log2 fold
change q-value
SMURF2 AU157259 9.00 ,0.01
LIFR NM_002310 8.00 ,0.01
HEXB NM_000521 3.36 ,0.01
C1orf107 NM_014388 4.46 0.01
ATF1 CA337502 3.00 0.02
NRAS NM_002524 4.13 0.04
TACC1 AL133564 2.40 0.09
GPR137B NM_003272 2.00 0.1
YIPF5 AW001618 1.77 0.17
YES1 NM_005433 2.55 0.18
ATP5O NM_001697 1.08 0.26
TMED2 NM_006815 1.13 0.29
EXOC8 AI168350 1.00 0.29
MRPL15 NM_014175 2.13 0.44
PCNA NM_002592 0.72 0.53
ATP6V1C1 NM_001695 1.13 0.53
SCYL2 NM_017988 2.13 0.57
RRM2 BE966236 0.72 0.57
DLG7 NM_014750 1.13 0.57
KLHL12 AK024412 0.91 0.59
UBE2J1 NM_016021 0.72 0.62
SLMO2 BF032213 0.68 0.62
MLF1IP NM_024629 1.13 0.62
FAM33A BE048371 0.72 0.62
CCDC117 AW070234 0.81 0.62
TMTC3 AA428286 0.55 0.72
EIF3J BC002719 0.40 0.75
TOP2A AU159942 0.33 0.76
WASL AL523820 0.55 0.81
FIGNL1 NM_022116 0.55 0.81
ABCD3 BC009712 0.13 0.94
Genes were grouped according to the significance of them being enriched in
endothelial cells compared with non-endothelial cells based on expression
sequenced tags (ESTs). To account for multiple testing errors, an FDR was
employed to calculate the significance of the genes being endothelial enriched
(q,0.05). Bold text indicates genes that are significantly enriched in endothelial
cells with a q-value of ,0.05.
doi:10.1371/journal.pone.0044294.t005
Figure 4. Pie chart of differentially expressed genes in breast
IDC LCM blood vessels cross-referenced to endothelial cell
libraries. In-silico subtraction, employing maximum likelihood statis-
tics, between endothelial and non-endothelial pools found endothelial
enriched genes and were used to prioritise LCM candidate genes. To
account for multiple testing errors, a FDR was employed to calculate
the significance of the genes being endothelial specific (q,0.05).
doi:10.1371/journal.pone.0044294.g004
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We then compared the list of 63 genes that were upregulated in
IDC-associated blood vessels with a list of mouse stromal genes
that were downregulated following treatment with the anti-VEGF
agent (Bevacizumab) (For details on methods relevant to this
section see Supplementary Information, Method S1 and Fig-
ure S3). This allowed the identification of IDC-associated blood
vessel genes that were likely to be regulated by VEGF.
Bevacizumab is an anti-angiogenic agent that prevents human
VEGF from binding and activating VEGF-receptor 2 on
endothelial cells, resulting in the downregulation of stromal genes
that contribute to angiogenesis. We injected BALB/c SCID mice
with human U87 tumour cells and then treated the mice with
Bevacizumab or placebo. Whole tumours, including tumour
stroma, were then analysed using mouse-specific arrays. This
approach enabled us to examine the effect of Bevacizumab on
downregulating genes in the mouse tumour stroma. By cross-
referencing the IDC blood vessel gene list with the genes
downregulated after Bevazicumab treatment, we show that the
greatest proportion (65%) of the genes upregulated in IDC blood
vessels are also downregulated in the tumour stroma after
Bevacizumab treatment. The results from this combined approach
indicate that we have identified a group of genes that may also
play an important part in VEGF-mediated angiogenesis. These
data thus provided us with a further suggestion of the potential
angiogenic function of the genes that were upregulated in IDC-
associated blood vessels.
Identifying genes enriched in endothelial cells
Targeting endothelial cells, specifically, is one approach to
reducing the potential side-effects of novel anti-angiogenic
strategies. Thus, we asked whether any of the genes that were
upregulated in IDC-associated blood vessels were also enriched in
endothelial cells. Earlier work from Herbert et al. found endothe-
lial cell enriched genes using cDNA libraries [37]. By cross-
referencing these genes with IDC-associated vessel genes, we
found 6 genes that were expressed significantly in endothelial cells
(q,0.05) compared with non-endothelial cells (Figure 4).Table 5
shows the list of endothelial-expressed genes where SMURF2,
LIFR, HEX-B, C1orf107, ATF1 and NRAS were enriched
significantly in endothelial cells (q,0.05). Together, these results
indicate that by using this approach we can identify not only genes
that are upregulated significantly in blood vessels associated with
Figure 5. Validation of GPR164 and LIFR microarray expression data by immunofluorescence staining of human normal breast and
IDC. Representative confocal images of vessels from normal and IDC breast sections immunostained for CD31 and either GPR164 (A) or LIFR (B).
Relative expression levels were quantified and means + s.e.m. are given for each antigen. n = 6 individual tissue samples, *p,0.05, { p,0.06, scale
bars 50 mm.
doi:10.1371/journal.pone.0044294.g005
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human breast IDC, but also further refine the list to mark those
with an enriched expression profile in endothelial cells.
Immunofluorescence validation of GPR164 and LIFR
The object of this study was to discover novel functional
regulators of angiogenesis. Since mRNA levels do not always
correspond to either protein levels or functionality, they may have
limited physiological relevance. Thus we examined protein
expression levels and functionality of a subset of candidate
molecules identified in the arrays. In addition to the list of
endothelial-enriched genes and those that were also downregulat-
ed by Bevacizumab, for validation purposes, we analysed the
expression of proteins that are encoded by differentially regulated
IDC genes that have no known roles in angiogenesis but were
expressed at the cell surface. For example, GPR164 and LIFR are
both found at the cell surface. By immunofluorescence microscopy
we showed that GPR164 and LIFR were differentially expressed
in breast IDC compared to normal breast samples, as our
differential gene expression arrays predicted (Figure 5). Immu-
nofluorescence for other candidate proteins was not technically
possible due to the lack of antibody reactivity in whole tissue
sections.
Identifying novel anti-angiogenic targets
Given that our goal, was to identify targets with anti-angiogenic
potential we focused on siRNA-depletion of these candidate genes
in aortic ring assays. We examined the angiogenic capacity of a
subset of the 63 genes that were upregulated significantly in IDC-
associated blood vessels. This subset of genes were selected on
either their known cellular functions and/or enriched expression
in endothelial cells. The selected genes included NRAS, SMURF2,
ATF1 and HEX-B because of their high expression in endothelial
cells. In addition, given that LIFR was downregulated in IDC-
associated blood vessels this gene was also included as a potential
negative regulator of angiogenesis. GPR164 was selected because it
is expressed at the cell surface, making it potentially targetable,
and has been shown to be upregulated in prostate cancer [45].
RRM2 was selected because this molecule has been shown to be
involved in cell proliferation and associated with VEGF produc-
tion in cancer cells, but never studied in endothelial cells [46].
siRNA depletion of these genes in aortic ring assays was used to
determine their role in inhibiting VEGF-induced angiogenesis.
The degree of knockdown was confirmed by real-time PCR
(Methods S1 and Figure S4). Aortic rings were treated with
siRNA for 24 hr, and cultured in 30 ng/ml VEGF or PBS as a
control for up to 10 days (Figure 6). Aortic rings responded to
VEGF-stimulation with a significant (p,0.05) increase in micro-
vessel number compared with PBS treated aortic rings
(Figure 6B). Treatment with siRNA against Rrm2, Atf1 and
Hex-B, reduced VEGF-stimulated microvessel sprouting signifi-
cantly when compared with SCM siRNA treated aortic rings
(p,0.05). No significant decrease in microvessel sprouting was
observed with siRNA against Lifr, Gpr164, Nras or Smurf2. These
results indicate that Rrm2, Atf1 and Hex-B are positively involved in
VEGF induced angiogenesis. Thus, our results establish novel
roles for these molecules in VEGF-induced angiogenesis. Together
these results suggest that, RRM2, ATF1 and HEX-B may be good
candidates for anti-angiogenic therapy.
Discussion
The VEGF-signalling blocker Bevacizumab, can provide overall
survival (OS) benefit in colorectal, renal and some breast cancer
patients [47–50]. Unfortunately however, not all anti-angiogenic
approaches have been as successful and differential tumour
responses, even for Bevacizumab, may reflect differential blood
vessel molecular profiles from varying tumour types [5–9]. For
example, phage-display peptide libraries have demonstrated
heterogeneity in tumour-associated blood vessels [11–14]. In
addition, blood vessels from ovarian cancer, lung cancer and
melanoma have been reported to express significantly different
vascular molecular profiles [5]. Importantly, results between
studies have not always identified the same molecular profiles for
tumour associated blood vessels possibly reflecting different
methodological approaches. However, if we accept that different
tumours have different vascular molecular profiles, we hypothesise
that effective anti-angiogenic treatments will likely rely on tailoring
new anti-angiogenic drugs to specific cancer vascular profiles.
Previously, the pit-falls in identifying specific cancer-associated
vascular profiles have been related to methodology: expression
analyses were done either on cultured cells or on whole cancer
samples. The problem being that these systems do not discriminate
blood vessels from the rest of the cancer and can also introduce
molecular changes associated with culturing cells [6–8]. In
addition, knowing which blood vessel marker to use has been an
issue. For example, selection of CD146-positive cells from
colorectal cancer [8] was used to identify blood vessel. However
CD146 is also expressed in smooth muscle cells, which are
abundant in this cancer type, suggesting that any differential gene
expression data would include both myofibroblast and blood vessel
genes. Here, we have overcome such problems by using laser
capture microdissection of CD31-positive blood vessels to isolate
blood vessels without altering, drastically, their molecular make-
up. Although previous work has demonstrated that LCD of factor
VIII-positive blood vessels identifies differentially regulated genes
associated with breast cancer, none of these genes are proven to
have anti-angiogenic efficacy. This is likely because factor VIII is
not a marker of angiogenic, but rather quiescent, blood vessels and
is also found in adjacent extracellular matrix [9,30,51–54]. In
addition, we have used the 2-cycle amplification Nugene Ovation
kit to amplify RNA, which is preferable to the T7Oligo(dT)
method used by Bhati et al. [9,55] because it has the advantage of
amplifying higher numbers of genes from small amounts of RNA
[55]. Variations in the differentially expressed genes identified by
us or other groups [5,9] likely reflect differences in either the
cancer types studied, or the method used.
We have identified 70 differentially regulated genes that are
associated with CD31-positive blood vessels in human breast IDC
when compared with normal breast (5 fold or more, q,0.05).
These genes potentially encode biomarkers and/or anti-angiogen-
ic targets relevant to breast cancer. Given that vascular maturity is
defined as vessels with a defined basement membrane and
endothelial cells with close cell-cell junctions and association with
pericytes/smooth muscle cells [56], LCM captured vessels may
also contain some supporting cells and our data may highlight
genes associated with vascular maturity. This would be of interest
Figure 6. Depletion of Rrm2, HexB and Atf1 inhibits VEGF-stimulated angiogenesis. (A) Confocal micrographs of aortic ring microvessel
sprouting immunostained with BS1-lectin (green) and DAPI (blue) following growth in serum free media or 30 ng/ml VEGF and treatment with siRNA
targeting scrambled control (SCM), Lifr, Gpr164, Nras, Smurf2, Rrm2, Atf1, and Hex-B. (B) Bar-chart represents mean number of microvessel sprouts/
aortic ring given relative to SCM with VEGF + s.e.m. *p,0.05, nsd, no significant difference. n = 12–24 aortic rings per test. Scale bar, 200 mm.
doi:10.1371/journal.pone.0044294.g006
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to pursue since vascular maturity has been associated with
resistance to anti-VEGF therapy [57].
By comparing our differentiated gene list with genes that were
regulated by inhibiting VEGF with Bevacizumab in human
glioblastoma U87 xenografts, we found that 65% that were highly
expressed in IDC blood vessels were also downregulated by
Bevacizumab. A glioblastoma cell line was chosen, in these
xenograft experiments, because it is highly vascularised, repro-
ducible, does not have a high basal necrosis and responds well to
Bevacizumab. Glioblastoma is also a tumour type for which
Bevacizumab is approved. Since hypoxic cancer cells are the
major source of VEGF, the effect of Bevacizumab, which is
specific to human VEGF, was selected. Although comparison of
our data with EST libraries may be limited by the exclusion of any
genes that are enriched only in supporting cells, our result suggests
that the genes that were found to be highly expressed in breast
IDC associated vessels may also play an important part in VEGF-
mediated angiogenesis.
To inhibit angiogenesis it may be important to target
endothelial cells specifically. By comparing the list of 63 genes
that are upregulated significantly in IDC associated blood vessels
with genes found to be enriched in endothelial cell ESTs, six were
significantly expressed in endothelial cells compared with non-
endothelial cells. Indeed we have shown that out of the endothelial
enriched genes, Smurf2, Hex-B, Atf1, and Nras, plus Rrm2, which has
known roles in tumour biology, that depletion of Rrm2, Atf1 and
Hex-B have anti-angiogenic consequences in ex vivo mouse aortic
ring assays. These data validated our approach in the discovery of
novel anti-angiogenic targets.
The RRM2 gene encodes a ribonucleotide reductase small
subunit of ribonucleotide reductase enzyme (RNR) [58] and plays
an essential role in DNA synthesis, repair and cellular proliferation
[59]. A role for RRM2 in blood vessels has not been documented,
but it can enhance angiogenesis by upregulating VEGF in
oropharyngeal carcinoma cells [46]. The downregulation of
RRM2 by Bevacizumab, suggests that it is VEGF-regulated.
Together our data, with previous studies, suggest that inhibiting
RRM2 may have anti-angiogenic and anti-tumour effects.
HEX-B (hexosaminidase subunit beta) is involved in catalysing
the degradation of the ganglioside GM2 [60]. The role for HEX-B
in angiogenesis has not been explored previously, but ganglioside
can modulate cell signalling. Gangliosides shed by tumour cells
can also enhance VEGF-induced angiogenesis [61–64]. In
addition, recent studies have indicated that interferon tau (IFNT)
treatment of cycling ewes increases the endometrial expression of
HEXB and that this was associated with increased Hif-1a levels
[65]. Bevacizumab treatment is also known to increase hypoxia in
the tumour environment and Hif-1a expression [66]. Thus it is
temping to speculate that this regulates the increased HEXB in our
Bevacizumab experiments. How HEX-B in endothelial cells
regulates angiogenesis will need further investigation.
ATF1 regulates downstream target genes involved in growth
and survival [67–69]. In endothelial cells ATF1, when phosphor-
ylated, has been shown to upregulate COX2 [70]. Since VEGF
also upregulates COX2, and this correlates with increased tube
formation [71], we speculate that high expression of ATF1 in IDC
blood vessels may enhance endothelial cell responses to VEGF.
Indeed our data corroborate this, since depletion of ATF1 can
reduce VEGF-mediated angiogenesis.
In summary, we have successfully combined CD31 immuno-
staining and LCM to analyse gene expression in breast cancer
associated blood vessels. Although beyond the scope of this study,
future work will establish the biomarker value of the 63 genes that
are upregulated in blood vessels associated with human breast
cancer. Moreover, since siRNA depletion of Hex-B, Atf1 and Rrm2
inhibit VEGF-stimulated angiogenesis, our approach has demon-
strated novel anti-angiogenic targets. Future work will be required
to investigate their in vivo roles.
Supporting Information
Figure S1 CD31-positive blood vessels are negative for
the myeloid marker CD68 in human breast cancer. For
laser capture microscopy we identified blood vessels by their
expression of CD31 (red) and their morphology i.e., structures with
a clear lumen and or branched morphology. However, CD31 has
also been shown to be expressed in some myeloid cells. Here we
demonstrate that CD31 structures, with a clear lumen and or
branched morphology are CD68 (green) negative, a biomarker for
myeloid cells. Our results suggest that CD31-LCM captured blood
vessels from breast samples were myeloid negative.
(TIF)
Figure S2 RNA profile of the six LCM captured samples
used for gene expression array. (A) RNA gel-like profile and
(B) histograms of RNA samples analysed with an Agilent
bioanalyser. The 28S and 18s distinctive ribosomal RNA bands
were observed in all 6 samples, and RIN ranged from 6–9.1.
(TIF)
Figure S3 Transcripts in the upregulated IDC vessel
signature that respond to anti-VEGF treatment. Compar-
ison of upregulated laser capture blood vessel human IDC genes
with those differentially expressed in the mouse tumour stroma
following Bevacizumab treatment. U87 xenograft bearing mice
were treated, or not, with Bevacizumab and stromal gene profiles
were compared with the human IDC blood vessel gene signature.
C1–C5, controls; BEV1-BEV4, Bevacizumab-treated tumour
stromal samples. Out of the 51 genes that were upregulated in
human IDC blood vessels, 41 genes were down regulated
following Bevacizumab treatment indicating their possible in-
volvement in VEGF-stimulated angiogenesis. Colour scale indi-
cated genes that were upregulated (red) or down-regulated (blue)
in the endothelial cell signature. The heat-map is standardised per
gene.
(TIF)
Figure S4 Gene expression following siRNA treatment.
(A) Primary endothelial cells and (B) aortic rings were transfected
with indicated siRNA and mRNA expression was measured by
real-time PCR. Scrambled (SCM) siRNA was used as a negative
control. Gene expression is given as a ratio to Actin mRNA
expression, as an internal control, and the data in the graph is
presented as fold-change relative to control sample. p,0.05, n= 3.
(TIF)
Methods S1 Methods and Materials used for supple-
mentary data.
(DOC)
Table S1 List of genes and their primer sequences used
for validating differentially expressed genes in primary
mouse endothelial cells with qPCR.
(DOCX)
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